 Home > Active Ingredient News > Antitumor Therapy > 2021 ASCO: The Voice of China in the Field of Hepatocellular Carcinoma

2021 ASCO: The Voice of China in the Field of Hepatocellular Carcinoma

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

dexmethylphenidate 5 mg

diatomaceous earth cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

202164，——（ASCO）

2021 On 6 Yue 4 , the world's oncology annual event - the American Society of Clinical Oncology ( ASCO ASCO ) Annual Meeting kicked off

Dose optimization of lenvatinb in clinical practice for patients with unresectable hepatocellular carcinoma

lenvatinb dose in clinical practice in patients with unresectable hepatocellular carcinoma optimization lenvatinb dose in clinical practice in patients with unresectable hepatocellular carcinoma optimization lenvatinbdose in clinical practice in patients with unresectable hepatocellular carcinoma Optimization

Lenvatinib has become the first-line treatment for patients with unresectable hepatocellular carcinoma ( u-HCC )

A research team from the Liver Cancer Institute of Zhongshan Hospital, Fudan University, Shanghai, evaluated the safety and anti-tumor activity of two lenvatinib administration strategies in the Chinese population .

In this study, the researchers included from 2018 Nian 4 months to 2019 Nian 7 Monthly accepted lenvatinib be u-HCC patients treated

The results show that included a total of 56 is patients, dose escalation group wherein 37 [ patients in the standard dose group .

The baseline demographic parameters between the two groups were comparable ( P>0.

Therefore, the lenvatinib dose escalation strategy may be an alternative therapy for patients during the treatment period

Chinese hepatocellular carcinoma ( HCC factors aid treatment decisions in patients) Chinese hepatocellular carcinoma ( HCC factors) in patients with adjuvant therapy decisions Chinese hepatocellular carcinoma (HCC) in patients with adjuvant therapy decision-making factors

This study aims to understand the decision-making factors of patients with adjuvant treatment after hepatocellular carcinoma ( HCC ) resection in China .

The study used a questionnaire ( https://pro.

The questionnaire survey covers three aspects: decision-making of adjuvant treatment, choice of treatment plan and the influence of risk of recurrence on willingness to receive adjuvant treatment, and it is scored from 1 (no impact) to 7 (high impact)

The results showed that a total of 2220 valid answers were collected .

Most interviewees ( 75% ) believe that doctors are the decision makers in the use of adjuvant treatment and treatment options

Therefore, most patients receive adjuvant therapy, the most common of which is systemic therapy and most patients receive adjuvant therapy, the most common of which are systemic therapy and TACE

lenvatinib joint TACE treatment of unresectable hepatocellular carcinoma: China retrospective analysis of real-world evidence lenvatinib joint TACE treatment of unresectable hepatocellular carcinoma: a retrospective analysis of China real world evidence lenvatinibjoint TACE treatment of unresectable hepatocellular carcinoma: China Retrospective analysis of real-world evidence

TACE and lenvatinib have been proven to prolong the overall survival of patients with
unresectable HCC .
The combination of the two can also improve clinical efficacy, and has been widely used in the real world .
However, the best time to add lenvatinb to TACE is still unclear .
The study aims to evaluate the efficacy and safety of two combined strategies in the treatment of unresectable hepatocellular carcinoma .

TACE and lenvatinib are proven to prolong unresectable HCC.
TACE and lenvatinib are proven to prolong the overall survival of patients with unresectable HCC .
The combination of the two can also improve clinical efficacy and is widely used in the real world
.
However, in the overall survival of patients, the combination of the two can also improve clinical efficacy, and has been widely used in the real world
.
The best time to add lenvatinb to TACE is still unclear .
The study aims to evaluate the efficacy and safety of two combined strategies in the treatment of unresectable hepatocellular carcinoma .

Researchers from the Chinese Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai storage from the 2018 Nian 11 months to 2020 Nian 6 months, 79 patients received TACE and lenvatinib combination therapy, follow-up Chaoguo 2 months, and is divided into early combination therapy Group ( addition of lenvatinib before or after the first TACE ) and advanced combination therapy group ( addition of lenvatinib after at least two TACE operations ) .
The tumor response and progression-free survival ( PFS , the time from the first day of lenvatinib to the progression or death of the disease) were evaluated according to the RECIST1.
1 standard , and liver function evaluation was performed at baseline and every 2 months .

The results showed that a total of 48 patients with unresectable HCC were admitted, and the median follow-up time for all patients was 9.
3 ( 5.
3-14.
3 ) months
.
The baseline characteristics of the two groups of patients were similar
.
Early combination group ( n-22 is = ) and late combination group ( n-= 26 is the average age) were 65 ± 9.
7 years, and 61 ± 11.
6 years; BCLC C of HCC accounted for 59% and 54 is% ( P = 0.
89 ); Child- The proportion of Pugh A is 81.
8% and 77% ( p=0.
73 )
.
Objective response rate (ORR ) ( 18.
2% vs 26.
9% , P=0.
51 ) and disease control rate ( 90.
9% vs 92.
3% , P=1.
00) There is no significant difference
.
The median PFS of the early combined treatment group was significantly longer than that of the late combined treatment group ( 14.
5 months vs 8.
9 months; P=0.
048 )
.
The safety status of the two groups was similar
.
Grade 3/4 adverse events were 3 cases ( 13.
6% ) and 2 cases ( 7.
7% ) ( P=0.
65 )
.

Therefore, this study is the first real-world data on the timing of the combination of lenvatinib and TACE to treat patients with unresectable HCC so far .
For patients with longer mPFS , an early combination therapy strategy may be a better choice .

Therefore, this study is the first real-world data on the timing of the combination of lenvatinib and TACE in the treatment of patients with unresectable HCC .
For patients with longer mPFS , an early combination therapy strategy may be a better choice .

Real-world data on the timing of the combination of lenvatinib and TACE in the treatment of patients with unresectable HCC .
For patients with longer mPFS , an early combination therapy strategy may be a better choice .

FOHAIC-1 study: Comparing the efficacy of hepatic arterial infusion chemotherapy ( HAIC ) and sorafenib in advanced hepatocellular carcinoma

FOHAIC-1 advanced hepatocellular carcinoma in contrast hepatic arterial infusion chemotherapy (: Research HAIC efficacy) and sorafenib treatment FOHAIC-1 study: advanced hepatocellular carcinoma in contrast hepatic arterial infusion chemotherapy ( HAIC ) and sorafenib efficacy FOHAIC-1study: advanced hepatocellular carcinoma in contrast hepatic arterial infusion chemotherapy (HAIC) and sorafenib efficacy

The FOHAIC-1 study led by Professor Ming Zhao from Sun Yat-sen University Cancer Hospital aims to evaluate the effect of HAIC-FOLFOX regimen as a first-line treatment for aHCC patients with heavier intrahepatic tumor burden , while looking for biomarkers related to benefit .

This is an open-label phase 3 study.
Patients with advanced hepatocellular carcinoma who have not been systematically treated were enrolled in randomized to receive FOLFOX regimen of hepatic arterial infusion chemotherapy ( HAIC ) or sorafenib at a ratio of 1:1 .
.
The baseline intrahepatic tumor burden of the enrolled patients was large, of which more than 80% had portal vein tumor thrombi, the median tumor diameter was more than 10 cm , and the intrahepatic tumor burden exceeded 50% of the patients reached more than 40% .

2017 years 5 months to 2020 years 5 during the month, were enrolled 260.
patients
.
The primary end point, HAIC group OS significantly better than sorafenib (median OS were 13.
9 months and 8.
2 months, the HR = 0.
408 , P <from 0.
001 )
.
In the HAIC group, 16 patients ( 12.
3% ) achieved tumor downgrading, and 15 of them received radical surgery or radiofrequency treatment.
The median OS of these patients was 20.
8 months, and the 1- year survival rate was 93.
8%
.
The OS of the HAIC group was significantly better than that of the sorafenib group (median OS were13.
9 months and 8.
2 months, the HR = 0.
408 , P <from 0.
001 )
.
In the HAIC group, 16 patients ( 12.
3% ) achieved tumor downgrading, and 15 of them received radical surgery or radiofrequency treatment.
The median OS of these patients was 20.
8 months, and the 1- year survival rate was 93.
8%
.

Lun cutting imatinib + AK104 for first-line treatment of unresectable hepatocellular carcinoma

Lun cutting imatinib + AK104 for treating unresectable hepatocellular carcinoma line Lun cutting imatinib + AK104 for unresectable hepatocellular carcinoma line treatment Lun cutting imatinib+ AK104for first-line treatment of unresectable hepatocellular carcinoma

AK104 is a humanized IgG1 bispecific antibody that can simultaneously bind PD-1 and CTLA-4
.
This multicenter, single-arm, phase II study enrolled 30 unresectable aHCC patients ( 93.
3% HBV positive) who received AK104 ( 6mg/kg , q2w ) + lenvatinib (standard dose) as the first-line treatment
.

AK104 is a humanized IgG1 bispecific antibody that can simultaneously bind PD-1 and CTLA-4 AK104 is a humanized IgG1 bispecific antibody that can simultaneously bind PD-1 and CTLA-4
.
The multi-center,
single-arm, .
The phase II study included 30 unresectable aHCC patients ( 93.
3% HBV positive) who received AK104 ( 6mg/kg , q2w ) + lenvatinib (standard dose) as the first-line treatment
.

Among the currently evaluable 18 patients, the efficacy data looks very good.
The ORR evaluated by RECIST v1.
1 reached 44.
4% and the DCR was 77.
8% .
The median PFS was not reached .
In terms of safety, the incidence of treatment-related adverse events of grade 3 and above was 26.
7% .

At present, the use of CTLA-4 antibody is discontinued after a short period of use in order to reduce the incidence of adverse events.
It is expected that such drugs will be launched in China as soon as possible
.
In contrast, individuals are not very looking forward to bispecific antibodies.
Instead of using a fixed combination of bispecific antibodies, it may be better to freely combine the two antibodies
.

At present, CTLA-4 current, CTLA-4 antibody use is stopped after a short period of use in order to reduce the incidence of adverse events.
It is expected that such drugs will be launched in China as soon as possible
.
In contrast, individuals are not very looking forward to bispecific antibodies.
Instead of using a fixed combination of bispecific antibodies, it may be better to freely combine the two antibodies
.
The use of antibodies is stopped after a short period of use to reduce the incidence of adverse events.
It is expected that such drugs will be launched in China as soon as possible
.

The RESCUE study is updated again, and the Shuangai program has obtained breakthrough median OS data for liver cancer first and second line !

The RESCUE study is updated again, and the Shuangai program has obtained breakthrough median OS data for liver cancer first and second line ! The RESCUE study is updated again, and the Shuangai program has obtained breakthrough median OS data for liver cancer first and second line ! The RESCUEstudy is updated again, and the Shuangai program has obtained breakthrough medianOSdatafor liver cancer first and second line!

At this ASCO annual meeting, " Shuang Ai Combination " has a total of 5 studies
in the field of hepatocellular carcinoma for data announcement and result update .
Among them, the RESCUE study of carrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma led by Professor Xu Jianming updated the overall survival (OS) results .
The median OS of the first-line treatment cohort was 20.
1 months, and the 2- year OS rate was 43.
3% , the median OS of the second-line treatment cohort was 21.
8 months, and the 2- year OS rate was 44.
6% , demonstrating the benefits of the " double AI regimen " for advanced hepatocellular carcinoma (HCC) .

At this ASCO annual meeting, " Shuang Ai Combination " has a total of 5 studies
in the field of hepatocellular carcinoma for data announcement and result update .
Among them, the RESCUE study of carrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma led by Professor Jianming Xu updated the overall survival (OS) results .
The median OS of the
first - line treatment cohort was 20.
1 months.
The 2- year OS rate was 43.
3% , the median OS of the second-line treatment cohort was 21.
8 months, and the 2- year OS rate was 44.
6% , demonstrating the benefits of the “ double AI regimen ” for advanced hepatocellular carcinoma (HCC) .
The OS is 20.
1 months, and the 2- year OS rate is 43.
3%The median OS of the second-line treatment cohort was 21.
8 months, and the 2- year OS rate was 44.
6% , demonstrating the benefit of the “ double AI regimen ” for advanced hepatocellular carcinoma (HCC) .

The team of Professor Gong Liansheng from Xiangya Hospital of Central South University also retrospectively analyzed the correlation between the clinical results of carrelizumab combined with apatinib in the treatment of unresectable hepatocellular carcinoma and patient characteristics.
A total of 26 patients with unresectable HCC were included.
, " double Ai combination of " objective response rate (ORR) was 57.
7% and disease control rate (DCR) of 84.
62% , the median progression-free survival (PFS) was 11 months, median OS was 18.
2 months, the The study evaluated the efficacy of carrelizumab combined with apatinib in the real world, but a larger sample size and longer-term follow-up are still needed to verify the results
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.